Can watching and waiting beat early treatment for Slow-Growing head and neck tumors?

NCT ID NCT07784595

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial asks whether monitoring a slow-growing head and neck tumor without immediate treatment can preserve quality of life better than early surgery or radiation. Adults with newly diagnosed carotid or vagal paragangliomas are randomly assigned to either active surveillance or immediate intervention. The study tracks how long it takes for functional decline to occur, using quality-of-life scores, and compares outcomes between the two approaches.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Active surveillance (watchful waiting) compared with immediate intervention (surgery or radiation therapy)
What this could lead to
If active surveillance proves better, patients with these slow-growing tumors might avoid unnecessary treatment and preserve quality of life longer.
What could go wrong
This is a randomized trial, but results may not apply to all patients. Active surveillance carries a risk of tumor growth or symptom development, and treatment may be needed later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 122 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 18 years-old, * Diagnosis of carotid or vagal HNPG with a largest diameter more than 10 mm * Diagnosis confirmed by imaging reading (MRI of CT scan) from less than 6 months, * Study eligibility validated in multidisciplinary discussion, * Patient followed in the reference center, * Preliminary written informed consent before any study-specific intervention Exclusion Criteria: * Patient with initial nerve palsy due to the evaluated HNPG, * Patient with non-typical presentation suggestive of aggressiveness (tumor pain, atypical imaging, suspicious lymphadenopathy), * Malignant HNPG identified by extra cervical lesion on metabolic imaging, * More than one HNPG at inclusion * Secreting HNPG defined as plasma or urine metanephrine or normetanephrine more than 2 times ULN, * Patient already treated with cervical radiotherapy, * Patient already treated with systemic therapy for another pheochromocytoma or paraganglioma, * Patient with another evolutive disease or other condition resulting on a life expectancy of less than 5 years at the investigator's discretion, * Patient unable or unwilling to be treated at the study center * Patients currently enrolled in another interventional study including investigational medicinal products or device, * Female patients who are pregnant, lactating or women of child-bearing potential without highly effective methods of contraception * Persons deprived of their liberty by a judicial or administrative decision * Persons under psychiatric care * Persons admitted to a health or social institution for purposes other than research * Adults subject to a legal protection measure (guardianship, curatorship) * Persons not affiliated to a social security scheme or beneficiaries of a similar scheme

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck paraganglioma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Endocrinologie, diabète et nutrition - Hôpital de Hautepierre - CHRU de Strasbourg

    Strasbourg, 67091, France

  • Fédération d'endocrinologie, Hôpital cardiologique - Groupement Hospitalier Est - Hospices Civils de Lyon

    Bron, 69500, France

  • Médecine Nucléaire - Hôpital Pitié-Salpêtrière - AP-HP

    Paris, 75013, France

  • Service Endocrinologie Diabétologie Nutrition - Hôpital Nord Laennec - CHU de Nantes

    Saint-Herblain, 44800, France

  • Service Endocrinologie et métabolismes - Hôpital Européen Georges Pompidou - AP-HP

    Paris, 75015, France

  • Service ORL - Hôpital Lariboisière - AP-HP

    Paris, 75010, France

  • Service d'Endocrinologie - Hôpital Cochin

    Paris, 75014, France

  • Service d'endocrinologie, diabétologie et nutrition - Hôpital Haut-Lévêque - CHU de Bordeaux

    Pessac, 36604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.